BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) changes shares on Wednesday trading session, with a change of -0.47% or -$0.02 shares. The trading starts at $4.23 and closed at $4.23 throughout the day. The trading session low price was $4.09 and day high was $4.3172 on Wednesday, August 05. After the session, the Healthcare sector daily volume shifted to 6.07 million while its average volume is 8.81M. In other hand, the BCRX market cap reached to $755.40M.
On June 9, 2020, BRIEF-Biocryst Announces Berotralstat Expanded Access Program For Patients With Hereditary Angioedema In United States. According to the news reported on Reuters, * BIOCRYST ANNOUNCES BEROTRALSTAT EXPANDED ACCESS PROGRAM FOR PATIENTS WITH HEREDITARY ANGIOEDEMA IN UNITED STATES Source text for Eikon: Further company coverage:
Checking out the performance report which defines the increase or decrease of prices for a specific period. For the last 5 trading sessions, its performance is down -0.24% and down -22.18% for month. Its quarterly performance was 9.07% above, while its half year performance is up 38.71%. BCRX yearly performance stood at positive 41.75% and rise 22.03% for year-to-date. Current recommendation for BioCryst Pharmaceuticals Inc. is 2.10.
Earnings per share or EPS is an important financial measure, which defines the profitability of a company. BCRX EPS (TTM) for 12-month is -0.95. EPS for this year is 4.00%, while for the next year its value is -0.76. Its EPS Q/Q reached 13.50%. It has an EPS of -6.80% down for past five years and for the next five years will be up 19.90%.
Let’s take a look on the analyst recommendations on BCRX for the current month and previous month. For the current month, 6 of 9 analysts recommend stock as Buy while 0 as Sell, 0 as overweight, 0 as underweight and 3 as Hold. As compared with the previous month ratings, 8 analysts participate in stock recommendation. Out of 8, 0 rated it sell, 6 rated it as Buy and 2 as Hold Ratings. On the other hand, target price ranges from $5.00 – $13.00. Average target price for BCRX was reached at $8.71.
Blackrock Inc., Baker Brothers Advisors, LLC and Vanguard Group, Inc. (The) are the top three holders in BioCryst Pharmaceuticals Inc. (BCRX) stock. On Mar 30, 2020, Blackrock Inc. has 13.4 million shares which valued 26.79 million. On Mar 30, 2020, Baker Brothers Advisors, LLC owned 10.95 million shares which valued at 21.89 million. On Mar 30, 2020, Vanguard Group, Inc. (The) has a total of 8.77 million shares which valued at 17.54 million. In the end, Vanguard Group, Inc. (The) have 4.97% shares outstanding of BioCryst Pharmaceuticals Inc. (BCRX) on Mar 30, 2020. The insider ownership moved to 0.10% and institutional holding shifted to 72.30%.
The company posted an EPS (TTM) of -0.95. According to the most recent quarter report on (Jun 2020), 9 analysts estimated an average EPS of -0.25, while -0.34 EPS posted a year ago period. Analyst Estimated EPS for BCRX published in the report was -$0.3 – -$0.22 during the same period. Comparing with last year, the average estimated EPS was -0.34 which is lower than -0.24 which was posted for recent quarter EPS.
A brief look on simple moving average (SMA) that determines the market price can impact a market. The SMA for BCRX rise 26.39% for period of 200 days. SMA for 50 days was -9.24% which is showing red signal, while SMA-20 was -12.06%. The moving average value for BioCryst Pharmaceuticals Inc. (BCRX) is 3.6583 and 4.6857 for 200 and 50 days respectively.
Let’s take a look on the insider transactions, in which multiple shareholders are showing interest in BCRX stock. On Nov 18, Stonehouse Jon P, President & CEO, bought 50,000 trading shares at the cost of $1.45, which valued at 72500.0. On Nov 18, Sniecinski Megan, Chief Business Officer, bought 45,000 shares at the cost of $1.45, with total shares of 45,000. On Nov 18, LEE KENNETH B JR, Director, bought 5,000 shares at the cost of 1.45. After this transaction, LEE KENNETH B JR total shares reached to 15,252 which valued at 7250.0.